Shedding of oral pentavalent bovine-human reassortant rotavirus vaccine indicates high uptake rate of vaccine and prominence of G-type G1
| Autor: | Jukka Markkula, Timo Vesikari, Maria Hemming-Harlo |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Rotavirus
Protective immunity Genotype Stool sample Vaccines Attenuated medicine.disease_cause Rotavirus Infections Pentavalent vaccine Feces 03 medical and health sciences 0302 clinical medicine 030225 pediatrics Animals Humans Medicine Vaccines Combined 030212 general & internal medicine General Veterinary General Immunology and Microbiology business.industry Rotavirus Vaccines Public Health Environmental and Occupational Health Infant Rotavirus vaccine Virology Virus Shedding High uptake Vaccination Infectious Diseases Molecular Medicine business Reassortant Viruses |
| Zdroj: | Vaccine. 38:1378-1383 |
| ISSN: | 0264-410X |
| DOI: | 10.1016/j.vaccine.2019.12.007 |
| Popis: | Background Live oral pentavalent bovine-human reassortant rotavirus (RV) vaccine, RotaTeq®, contains bovine rotaviruses reassorted with human G-types G1, G2, G3 and G4, and P-type P[8]. Shedding of RotaTeq® vaccine, as studied by RT-PCR, has been shown to be more common than initially reported, and may include formation of vaccine-derived double-reassortant G1P[8] RVs. We studied the extent and duration of RotaTeq® vaccine virus shedding, genotypes shed, and clinical symptoms associated with shedding. Material and methods We enrolled a total of 301 infants who received RotaTeq® vaccine according to Finnish schedule at 2, 3 and 5 months of age. Stool samples were collected 5–10 days after the first and 0–7 days before the third dose of the vaccine. Additional stool samples 6 and 12 weeks later were collected if the second stool sample was positive. All stools were studied with RT-PCR for RV VP7, VP4 and VP6. Parents filled a symptom diary for a week after each vaccine dose. Results We found that 93% of the vaccinees shed vaccine related viral particles in one sample taken 5–10 days after the first dose, indicating that stool shedding is very common and may be regarded as a marker of successful vaccination. Genotype G1 was the predominant genotype in shedding, often in association with P[8], and the only genotype found in long-term shedding. Also G4 was commonly detected whereas other vaccine G-types and bovine-type P[5] were not. Conclusions Shedding of RotaTeq® vaccine-derived viruses is a sign for successful vaccination. Intense shedding of G1 with or without P[8]reflects effective multiplication and may be an important factor in the induction of protective immunity. Shedding of G1 containing vaccine viruses may be prolonged up to 8 months of age. These results suggest that the pentavalent vaccine functions largely like a monovalent G1 vaccine. Eudra-CT: 2014-004252-60. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect